Sensei Biotherapeutics Announces Board Member Resignation and Consultant Role

2mon ago, source: TipRanks on MSN

Samuel Broder, MD has stepped down from his role on the Board of Directors at Sensei Biotherapeutics, Inc., where he served ...

Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference

10d ago, source:

Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate ...

Buy Rating Affirmed for Sensei Biotherapeutics on Strong Fiscal Health and Promising Clinical Trials

1mon ago, source: Business Insider

Sensei Biotherapeutics (SNSE) Company Description: Sensei Biotherapeutics Inc is a clinical-stage immunotherapy company. It is engaged in the discovery and development of next-generation therapies ...

Sensei Biotherapeutics Inc Ordinary Shares

29d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

28d ago, source: Yahoo Finance

First quarter results came shortly after JNJ’s expansion in the cardiovascular space with the $13.1 billion acquisition of heart device firm Shockwave Medical Inc (NASDAQ: SWAV). First Quarter ...

Sensei Biotherapeutics CFO Erin Colgan to resign

17d ago, source: Investing

On Monday, Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a biopharmaceutical company, announced the upcoming resignation of Erin Colgan, the company's Chief Financial Officer (CFO). Ms. Colgan has ...

Sensei Biotherapeutics advances cancer therapy with new antibody

15d ago, source: Investing

BOSTON - Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company, announced the publication of a paper in Nature Communications that details the development of a novel antibody ...

Post-J&J bid, Sensei explores new oncology VISTAs

23d ago, source: BioWorld

An increasingly popular target across varied cancer types is the immune system regulator V-domain Ig suppressor of T-cell activation (VISTA), where a number of developers have taken early stage aim – ...

Sensei Biotherapeutics Inc (SNSE)

29d ago, source: Investing

Sensei Biotherapeutics, Inc. is an immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated ...

CLDI Calidi Biotherapeutics, Inc.

1d ago, source: Seeking Alpha

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in ...

Sensei Biotherapeutics Inc Ordinary Shares

15d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sensei Biotherapeutics advances cancer therapy with new antibody

14d ago, source: Investing

BOSTON - Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company, announced the publication of a paper in Nature Communications that details the development of a novel antibody, SNS-101 ...